Vistafin is insulin-mimicking adipocytokine secreted 
from visceral adipose tissue, which plays an essential role in a 
number of biological processes affected glucose uptake 
regulation, inflammation, immunity, insulin resistance, vascular 
calcification, capillary tube formation, endothelial cell function 
and angiogenesis. Circulating level of visfatin exhibits to be a 
sufficiently increased in MetS and Type 2 Diabetes Mellitus 
(T2DM) patients compared with healthy individuals. Several 
clinical studies have sshown that serum vitafin may predict 
Cardiovascular (CV) disease and CV events in MetS and T2DM 
patients. The review summarizes the various aspects of the role of 
vistafin as biomarker of MetS compared with commonly used 
biomarkers, i.e. adiponectin, leptin, resistin, apelin. In future more 
investigations are needed to better understand the role of vistafin 
in dysmetabolic-related disease and its ability to predict CV 
complications in these patient populations.